BRTX BRTX
Company Profile ↓Company Overview
BRTX (BRTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 36.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $359.70K (-10.3% YoY); net profit $-14.24M.
- Trailing 12 Months Year-on-year growth — revenue -10.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 36.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 36.11% |
| 1 Year: | -10.30% |
Stock Price Performance
| 1 Year: | -85.81% |
| 6 Months: | -80.91% |
| 3 Months: | -17.32% |
| 1 Month: | -43.58% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.43 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 36.1% over 5 years.
CONS
- Trading 88.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.00K | 37.00K | 26.00K | 29.00K | 31.00K | 38.00K | 26.00K | 19.00K | 15.00K | 18.00K | 15.00K | 8.00K | 16.00K | 71.10K | 29.00K | 31.30K | 64.50K | 30.70K | 35.00K | 89.10K | 233.60K | 25.00K | 303.30K | 11.80K | 23.17K |
| Gross Profit | 968 | 389 | 115 | 315 | 133.57K | 93.81K | 108.47K | 74.12K | 45.20K | 9.12K | 16.08K | 5.00K | 7.00K | 20.00K | 16.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 64.50K | 30.70K | 35.00K | 82.61K | 215.36K | 22.09K | 294.57K | 1.23K | 15.79K |
| Operating Income | -1.30M | -1.11M | -1.13M | -1.43M | -1.28M | -896.01K | -1.63M | -1.26M | -1.49M | -2.07M | -2.14M | -1.72M | -2.49M | -2.57M | -1.74M | -2.23M | -2.05M | -1.19M | -2.33M | -2.13M | -1.82M | -818.99K | -461.59K | -610.26K | -15.05M | -3.56M | -3.69M | -5.05M | -4.63M | -4.61M | -5.78M | -3.12M | -3.10M | -4.11M | -2.47M | -2.29M | -4.81M | -3.31M | -3.71M | -3.39M |
| Net Income | -1.57M | -1.25M | -1.30M | -1.67M | -1.33M | -1.10M | -1.76M | -1.42M | -1.62M | -2.49M | -2.26M | -1.83M | -2.79M | -2.75M | -2.05M | -2.51M | -3.51M | -2.93M | -3.88M | -4.16M | -5.06M | -7.55M | 2.88M | -836.26K | -15.65M | -4.06M | -4.18M | -4.82M | -4.68M | -4.66M | -7.17M | -5.71M | 4.77M | -2.22M | -4.03M | -1.09M | -5.34M | -2.66M | -3.04M | -2.15M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.24 | - | - | 0.00 | - | - | - | - | - | -1.28 | -1.28 | -1.93 | -1.47 | 0.39 | -0.33 | -0.50 | -0.13 | -0.64 | -0.30 | -0.33 | -0.12 |
| R&D Expense | 400.44K | 372.92K | 414.92K | 493.74K | 293.33K | 290.71K | 406.86K | 452.49K | 615.65K | 866.04K | 608.69K | 656.17K | 805.85K | 610.73K | 490.65K | 407.13K | 372.81K | 357.44K | 455.01K | 441.72K | 409.81K | 186.33K | 261.55K | 251.04K | 165.25K | 160.90K | 237.41K | 775.34K | 1.08M | 989.17K | 1.23M | 902.89K | 809.82K | 1.06M | 1.45M | 1.45M | 2.65M | 2.23M | 2.59M | 1.93M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 15.59K | 1.68K | 416.00K | 628.91K | 36.35K | 81.00K | 111.00K | 130.00K | 77.00K | 46.00K | 119.80K | 145.80K | 401.00K | 359.70K |
| Gross Profit | - | - | 0 | 14.28K | 1.47K | 202.16K | 367.41K | 36.25K | 81.00K | - | - | - | - | - | 145.80K | 372.93K | 335.86K |
| Operating Income | - | -2.07M | -3.55M | -5.57M | -4.75M | -4.92M | -7.17M | -7.79M | -8.37M | -7.65M | -8.43M | -2.75M | -26.31M | -18.97M | -15.22M | -11.56M | -15.65M |
| Net Income | -1.20M | -2.26M | -4.07M | -6.54M | -5.75M | -5.59M | -7.92M | -8.64M | -9.44M | -12.52M | -14.65M | -11.27M | -44.30M | -18.49M | -10.42M | -8.98M | -14.24M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.11 | -2.47 | -1.16 | -1.58 |
| R&D Expense | - | 11.62K | 12.00K | 756.78K | 1.59M | 1.43M | 2.11M | 2.88M | 2.15M | 1.51M | 1.72M | 876.83K | 729.06K | 3.51M | 4.03M | 6.71M | 10.09M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 468.51K | 220.97K | 1.27M | 1.38M | 1.69M | 2.02M | 1.58M | 1.76M | 1.19M | 1.47M | 4.35M | 22.45M | 16.43M | 12.61M | 12.28M | 4.08M |
| Total Equity | 0 | -51.09K | -744.22K | -3.69M | -5.14M | -6.69M | -6.89M | -3.91M | -5.00M | -6.84M | -8.64M | -12.78M | -1.33M | 21.60M | 10.29M | 10.00M | 8.53M | 356.74K |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.03M | 1.71M | 884.38K | 547.89K | 1.51M |
| Long Term Debt | - | - | 196.88K | - | - | - | - | - | - | - | - | - | - | 250.00K | - | - | - | - |
| Total Liabilities | - | - | 1.21M | 3.91M | 6.41M | 8.07M | 8.58M | 5.93M | 6.58M | 8.60M | 9.83M | 14.24M | 5.68M | 856.50K | 602.62K | 2.61M | 3.75M | - |
| Current Liabilities | - | - | 1.02M | 3.91M | 2.82M | 7.50M | 8.52M | 5.61M | 5.84M | 8.35M | 9.25M | 13.72M | 1.04M | 363.82K | 440.30K | 2.61M | 3.75M | 3.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -729.22K | -2.81M | -3.18M | -2.67M | - | - | - | -3.85M | -5.10M | -6.92M | -1.96M | -3.33M | -5.91M | -6.43M | -8.23M | -10.79M |
| Investing Cash Flow | -48.78K | 14.23K | -1.00M | -11.16K | - | - | - | -3.62K | -12.87K | -35.63K | - | -30.66K | -13.40M | 3.25M | 514.53K | 8.90M |
| Financing Cash Flow | 796.03K | 2.85M | 4.12M | 2.88M | - | - | - | 4.28M | 4.78M | 6.84M | 5.03M | 21.32M | - | 2.35M | 7.38M | 2.85M |
| Capital Expenditure | -45.38K | -17.77K | -2.53K | -11.16K | -168.38K | -408.07K | -188.76K | -3.62K | -12.87K | -35.63K | - | -30.66K | -265.22K | -171.04K | -106.19K | -116.07K |
| Free Cash Flow | -774.60K | -2.83M | -3.19M | -2.68M | - | - | - | -3.86M | -5.12M | -6.95M | - | -3.36M | -6.18M | -6.60M | -8.34M | -10.91M |
| Share Buybacks | 28.00K | 4.00K | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 91.6% | 87.6% | 48.6% | 58.4% | 99.7% | 100.0% | - | - | - | - | - | 100.0% | 93.0% | 93.4% |
| Operating Margin % | - | - | - | -35,746.1% | -282,873.2% | -1,183.3% | -1,140.1% | -21,414.0% | -10,338.6% | -6,889.8% | -6,486.2% | -3,574.1% | -57,191.0% | -15,838.1% | -10,439.5% | -2,881.6% | -4,350.1% |
| Net Margin % | - | - | - | -41,931.6% | -342,333.0% | -1,343.2% | -1,259.9% | -23,755.4% | -11,660.1% | -11,277.3% | -11,267.6% | -14,639.9% | -96,311.5% | -15,438.0% | -7,145.2% | -2,239.2% | -3,959.4% |
| ROE % | 2,343.3% | 304.2% | 110.5% | 127.1% | 86.0% | 81.1% | 202.7% | 172.7% | 138.1% | 144.9% | 114.7% | 846.6% | -205.1% | -179.7% | -104.1% | -105.3% | -3,992.2% |
| ROCE % | - | 378.1% | 96.4% | 360.0% | 77.7% | 72.0% | 199.4% | 182.5% | 127.0% | 94.9% | 68.8% | -83.3% | -119.1% | -118.6% | -152.1% | -135.4% | -4,386.1% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BRTX
BioRestorative Therapies (BRTX) investor Alta Partners reports 4.99% ownership cap - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOUFhXVDc2ckxSMUkyVDNrRGQ5dXVpUjRPQ3VwUWlJTFQwalJQUFFyODlDQ2hRbVdMQnI2a0RxT2xrWGwtQlFQeGpOcXpMODlsRnhtblM2cDJ3dHJ2ZWdsRXUxRy0zOER5VXFaa3ZYdDBaR0phNEhYSkZoa01hSWZiaHZYOXg2dkw1Nzltel…
What Makes Biorestorative Therapies (BRTX) a New Buy Stock - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNTUlXRktxS3hYRTZ4MU1NbXNPaW5Icy1yOWlZTHdhbjd2YzlxaHVmMU5BT0lCZFkzbk1MOThWODVlWDJkRG1VeVQ4Y04wdkE4NnZiUG5CSHAyNTNtOVBtc25yMEFfZS03MDhraTMwUU9LMXFhenZONDdDbUNTY3l2ZWRRaG0ya1h3ZFFEOX…
BIORESTORATIVE THERAPIES ($BRTX) Releases Q4 2025 Earnings, Stock Rises | BRTX Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQRk94ZlhaR2hJXzNyb2s4S1pDcmdza3p0Z056Z2VSTVdOb2VBR1JjNlY4dFpMRTR5MlkyZ2hnUWQ2WF9iTmM3WDVkS1NOMG9FTnF5Zi1sUW43Rm05aWpLZmRGTzRVQ3lkNndLWHdxZGZZRndBd1VnQ0VoVkZVcGVIOUEzY1R2MEJBbXZzSj…
BioRestorative Completes Phase 2 Dosing of BRTX-100, - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMimgJBVV95cUxQYUduRTlGeVhMYnZQVDVsVVBhVnpJUXJIMXRhcVdCaVphTkNoM1FDd2ZzcWlwTUFpYUFpLXdPWUNxQTl5MG9lZEZDMnU3Rk9rRnFRbmNFVXhraHBPcm42YThoa0xUVHJnSm1xQWNXVHRISXVGX3JUY2xQZnRoNkctcTV2YVVLcTlPUWd4bG…
BRTX|BioRestorative Therapies Inc|Price:0.214|Chg%:+0.016 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9HTlhWQ0s1YmctRmZnZ0xHTXRiYS1nejlwTllGRUtOd28zZnpEQVBxZkRDUDZxSVp6NkZtSjlod0VYQlRSamxlMDlTdnBSaG5lcFd0eEtmcHNlRGVMR2g1dlJ5REdkT0FTMUJIU0hR?oc=5" target="_blank">BRTX|BioRestorative…
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOQWtKdENqZll1aFJvMGljTnRxdW54WFZ4Szl0eks3YXI1RWdFSTNjZk5zLW1KdWpZQWN4NVVkZExmNHJkQUIxSTE3dVZSM0k2bzNNcE94SjZNQnhhWW9QVGkxX1RnNTIzdm1BOERHY1AxMlFYa0hkY2dQdjM4YWFGVHVOYzZqUTFFOXhoUE…
BRTX — Frequently Asked Questions
What is the current share price of BRTX?
As of 2026-08-05 17:25 PDT, BRTX trades at $0.21 on NASDAQ/NYSE. Its 52-week range is $0.17 to $1.84.
What is the P/E ratio of BRTX?
BRTX trades at a trailing price-to-earnings (P/E) ratio of -0.13.
Is BRTX a good stock to buy?
This page provides a data-driven analysis of BRTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.